Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States

Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States

SAN DIEGO, Feb 21, 2014 (GLOBE NEWSWIRE via COMTEX) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") INNV -10.38%  today announced the availability of its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in the United States ("U.S.").

EjectDelay(TM) is currently available online through the Company's website ( ) and the product's specific website ( ). The Company is also working with Consortia Health, our U.S. co-promotion partner for EjectDelay(TM) to place this product into urologists' offices throughout the U.S. The product will also be available in the future through Consortia Health's website ( ). The product is available in two sizes in the U.S. as a 2 ounce tube with a retail price of $19.99 and as a 5mL single use packet with a retail price of $2.99.

The EjectDelay(TM) product license has been approved in Canada and the Company expects to launch the product in the Canadian market in 2014.

About EjectDelay(TM) and Premature Ejaculation

EjectDelay(TM) is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada-compliant proprietary topical treatment containing the drug benzocaine and indicated for the treatment of delayed premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes. For more information visit .

Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman state, "Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe."

About Innovus Pharmaceuticals, Inc.

Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.

For more information, go to .


Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products, to successfully commercialize such products as EjectDelay(TM) and to achieve its other development, commercialization and financial objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

        CONTACT: Innovus Pharma Contact:
                 Kevin Holmes
                 Chesapeake Group
                 [email protected]
                 T: 410-825-3930